Latest Science News -- ScienceDaily
Breaking science news and articles on global warming, extrasolar planets, stem cells, bird flu, autism, nanotechnology, dinosaurs, evolution -- the latest discoveries in astronomy, anthropology, biology, chemistry, climate and environment, computers, engineering, health and medicine, math, physics, psychology, technology, and more -- from the world's leading universities and research organizations.
Huntington disease prevention trial shows creatine safe, slows progression
Feb 8th 2014, 13:07
The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging showed a treatment-associated slowing of regional brain atrophy, evidence that creatine might slow the progression of presymptomatic HD. The Massachusetts General Hospital (MGH) study also utilized a novel design that allowed participants -- all of whom were at genetic risk for the neurodegenerative disorder -- to enroll without having to learn whether or not they carried the mutation that causes HD.
"More than 90 percent of those in the United States who know they are at risk for HD because of their family history have abstained from genetic testing, often because they fear discrimination or don't want to face the stress and anxiety of knowing they are destined to develop such a devastating disease," says H. Diana Rosas, MD, of the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND), lead and corresponding author of the paper that will appear in the March 11 issue of Neurology and has been released online. "Many of these individuals would still like to help find treatments, and this trial design allows them to participate while respecting their autonomy, their right not to know their personal genetic information."
Among the ways that the mutated form of the huntingtin protein damages brain cells is by interfering with cellular energy production, leading to a depletion of ATP, the molecule that powers most biological processes. Known to help restore ATP and maintain cellular energy, creatine is being investigated to treat a number of neurological conditions -- including Parkinson disease, amyotrophic lateral sclerosis and spinal cord injury. Studies in mouse models of HD showed that creatine raises brain ATP levels and protects against neurodegeneration. Previous clinical trials of creatine in symptomatic HD patients have been limited in scale, involved daily doses of 10 grams or less, and did not provide evidence of potential efficacy. Based on the results of a pilot study at MGH that evaluated doses as high as 40 grams, participants in the current study received doses of up to 30 grams daily.
The phase II PRECREST trial enrolled 64 adult participants -- 19 who knew they carried the mutated form of the HD gene and 45 with a 50 percent risk of having inherited the HD mutation. Genetic testing, results of which were made available only to the study statistician and not to study staff or participants, confirmed the genetic status of those who had previously been tested and revealed an additional 26 presymptomatic carriers of the mutated gene, for a total of 47 participants with presymptomatic HD and 17 controls.
For the first 6 months of the trial, participants were randomized into two groups, regardless of gene status. One group received twice-daily oral doses of creatine, up to a maximum of 30 grams per day, the other received placebo. After that first phase, all participants received creatine for an additional 12 months. Participants were assessed at regular study visits for adverse effects, and dosage levels were adjusted, if necessary, to reduce unpleasant side effects. Additional tests -- cognitive assessments, measurement of blood markers and MRI brain scans -- were conducted at the trial's outset, at 6 months and at the end of the study period.
During the first phase of the trial more than three-quarters of those randomized to creatine tolerated a daily dose of 15 grams or more, and more than two -thirds tolerated the full 30-gram dose. Throughout the entire trial, a total of 15 participants -- including several who knew they carried the HD mutation -- discontinued taking creatine because of gastrointestinal discomfort, the taste of the drug, inconvenience, or the stress of being constantly reminded of their HD risk. Other than occasional diarrhea and nausea, few adverse events were associated with creatine.
In participants who carried the HD mutation, the MRI scans taken at the outset of the trial had revealed significant atrophy in regions of the cerebral cortex and basal ganglia known to be affected by the disease. Followup MRI scans at six months showed a slower rate of atrophy in participants taking creatine compared to those on placebo. At the end of the second phase, the rate of brain atrophy had also slowed in presymptomatic participants that started taking creatine after 6 months on placebo.
In addition to suggesting that creatine could slow the progression of HD, these results also imply that neuroimaging may provide a useful biomarker of disease modification in studies of other potential treatments. While participants with the mutation had performed less well than controls on the cognitive tests at the study outset, creatine treatment had no significant effect on those measures, possibly because the tests were not sensitive enough to detect subtle changes that might occur during such a brief time period, the authors note.
"The results of this trial suggest that the prevention or delay of HD symptoms is feasible, that at-risk individuals can participate in clinical trials -- even if they do not want to learn their genetic status -- and that useful biomarkers can be developed to help assess therapeutic benefits," says senior author Steven Hersch, MD, PhD, of MGH-MIND. "In addition, we believe our study design sets an important precedent for other genetic diseases and will help inform discussions of how clinical research can coexist with deep concerns about genetic privacy and patient autonomy."
The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.
This entry passed through the Full-Text RSS service — if this is your content and you're reading it on someone else's site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.
You are receiving this email because you subscribed to this feed at https://blogtrottr.com
If you no longer wish to receive these emails, you can unsubscribe here:
- Solidot: 政治倾向由生理决定，而非理智
- Solidot: 魁北克省要求店主将Facebook页面内容翻译成法语
- Solidot: 科学出版商移除一百多篇机器生成的假论文
- Solidot: 英国政府提出新规定允许“三亲胚胎”
- Solidot: 波音Black手机的更多细节公开
- Solidot: MtGox申请破产保护
- Solidot: Debian移植到OpenRISC架构
- Solidot: 2014年Gnome亚洲峰会定在北京举行
- Solidot: 用LED路灯提供移动服务
- Solidot: 印度空间研究组织公布载人太空船原型
- Solidot: 华纳兄弟将制作《Minecraft》电影
- Solidot: Tor正在开发匿名即时聊天工具
- Solidot: ArnoldC：出自施瓦辛格电影的编程语言
- Solidot: 明报前总编被砍引发新闻自由的担忧
- Solidot: MtGox关闭后火币网交易量暴增
- Solidot: GCHQ拦截雅虎用户的视频聊天，发现许多人裸聊
- Solidot: 中国成立网络安全最高委员会
- Solidot: 中国科学家认为短距离水下量子通信是可能的
- Solidot: 美国儿童正在变瘦
- Solidot: 美国一参议员呼吁封杀比特币
- Solidot: Opera迎来丰收的一年
- Solidot: Chris Anderson的开源无人机王国
- Solidot: 中国科学家成功去除猴子的特定基因
- Confirm your unsubscription from '网易数码频道：相机资讯'
- Solidot: GitHub公开文本编辑器Atom
- Solidot: 上海禁止早晚高峰使用打车软件
- Solidot: P2P僵尸网络
- Solidot: 波音为政府研发具有自毁功能的Android手机
- Solidot: 两款Ubuntu手机原型亮相MWC
- Solidot: 亚马逊的甜言蜜语
- Solidot: 确认的太阳系外行星数量增至1700颗
- Solidot: 三星Tizen OS：没有Android应用的Android克隆
- Solidot: Google被勒令移除反穆斯林视频
- Solidot: 用基于WebGL的BabylonJS把3D扫描模型分享给小伙伴
- Solidot: GreatFire.org合作新闻网站被屏蔽
- Solidot: 依靠IDE让你变成一位差劲的程序员？
- Solidot: 骆家辉：中国未来美好，需要尊重法治和保障人权
- Solidot: 暴雪证实计划向玩家出售60美元的90级角色升级商品
- Solidot: 中国智能电网投入超过美国
- Solidot: Android木马利用Tor隐藏指令服务器位置
- Solidot: Wolfram演示Wolfram语言
- Solidot: 传记作者曝光Julian Assange的秘密生活
- Solidot: 诺基亚XL：大屏大抱负
- Solidot: Servo：Mozilla试图重新发明浏览器
- Solidot: 朝鲜叛逃者用气球反击平壤
- Solidot: 防监听手机Blackphone的更多细节
- Solidot: Twitter用户剧透《壮志凌云》，派拉蒙发出DMCA通知
- Solidot: MtGox收到美国传票，日本着手调查
- Solidot: 评估报告称国际热核聚变实验堆存在严重管理问题
- Solidot: Portal 2 Beta for Linux版发布
- Solidot: 苹果督促亚利桑那州州长否决反同性恋法案
- Solidot: 世卫组织警告北京空气污染，气象局呼吁民众hold住
- Solidot: 福特车载信息系统用QNX替代Windows
- Solidot: 科学家用鱼线创造人造肌肉
- Solidot: 安全研究员开发出能绕过微软EMET的攻击代码
- Solidot: 新西兰因计算机系统问题向错误的司机开出2万罚单法
- Solidot: 新浪微博用户增长速度创下新低
- Solidot: Pony僵尸网络从感染者机器上窃走了价值22万美元的数字货币
- Solidot: 巴西和欧洲宣布铺设绕过美国的海底光缆
- Solidot: 三星发布Galaxy S5——防水版Galaxy S4
- Solidot: MtGox关闭交易，关闭网站
- Solidot: 用大数据监控分析员工行为
- Solidot: PLoS要求论文作者公开数据
- Solidot: 市场因素迫使污染大户钢厂倒闭
- Solidot: 中国扩增新闻道德委员会
- Solidot: LinkedIn发布中文版，取名领英
- Solidot: Google将发布新版Google地图
- Solidot: 月球遭遇有记录以来最明亮的小行星撞击
- Confirm your unsubscription from 'Latest Science N...
- Solidot: 报告称95%的野鸡大学文凭授予了中国人
- Solidot: 哈佛超算集群被劫持挖掘狗币
- Solidot: 数字电影能保存100年吗？
- Latest Science News -- ScienceDaily: Synthetic ver...
- Latest Science News -- ScienceDaily: United Kingdo...
- Latest Science News -- ScienceDaily: New insights ...
- Solidot: 成人电影工作室用数字技术移除安全套
- Solidot: 神经学研究发现，程序语言确实像外语
- Solidot: 诺基亚公布三款Android手机
- Solidot: 腾讯金山等宣布向XP提供技术支持
- Confirm your unsubscription from '网易数码频道：家电资讯'
- Solidot: 微软证实Windows 8.1下一次更新将以非触摸设备为重心
- Solidot: 地球上最古老的岩石在澳大利亚
- Solidot: 香港首家比特币零售店周五开放
- Solidot: WhatsApp创始人用不可改签的机票向Facebook施压
- Solidot: NSA不再监听总理而去监听德国部长
- Solidot: 为什么专利和版权在中国难以实施？
- Solidot: gotofail：苹果 SSL/TLS 重大安全漏洞的细节
- Solidot: NASA公布宇航员拍摄的朝鲜夜晚照片
- Solidot: 中国律师要求公安部公布监控信息
- Solidot: Mozilla计划向新兴市场发布25美元智能手机
- Solidot: 高频交易员开始使用激光通信
- Solidot: 三星的智能手表运行Tizen
- Solidot: Stack Overflow公布用户调查结果
- Solidot: Chrome 33新变化引发用户强烈抗议
- Solidot: Bruce Schneier建议解散NSA
- Latest Science News -- ScienceDaily: Seed-filled b...
- Latest Science News -- ScienceDaily: Revolutionary...
- Latest Science News -- ScienceDaily: Is a 'buttery...
- Confirm your unsubscription from '网易科技频道IT业界新闻'
- Solidot: 数学模型预测革命
- ▼ 二月 (840)
- ► 2013 (16909)